Soleno Therapeutics (NASDAQ:SLNO) Shares Down 7.2% – Should You Sell?

Soleno Therapeutics, Inc. (NASDAQ:SLNO)’s stock price dropped 7.2% during mid-day trading on Friday . The company traded as low as $30.03 and last traded at $29.5780. Approximately 201,076 shares were traded during trading, a decline of 87% from the average daily volume of 1,588,168 shares. The stock had previously closed at $31.86.

Trending Headlines about Soleno Therapeutics

Here are the key news stories impacting Soleno Therapeutics this week:

• Negative Sentiment: A securities class action has been filed alleging material misstatements/omissions about Soleno’s Phase 3 DCCR program following the company’s November 5, 2025 disclosure of disappointing trial/launch information. Read More.
• Negative Sentiment: Kessler Topaz and other firms are soliciting investors and seeking lead‑plaintiff status in the same matter; the firm highlights alleged misstatements about DCCR safety/timeline and reiterates the May 5, 2026 lead‑plaintiff deadline. Read More.
• Negative Sentiment: Multiple national plaintiff firms (Rosen, Robbins Geller, Bernstein Liebhard, Pomerantz, Faruqi, Gross, Rosen, etc.) have issued investor alerts and filings reminding shareholders of the May 5 deadline and encouraging lead‑plaintiff applications—increasing the likelihood of coordinated litigation. Read More.
• Negative Sentiment: Faruqi, The Gross Law Firm and others are actively soliciting clients who suffered losses during the class period, signaling continued media/legal attention and possible consolidation of claims. Read More.

Analyst Ratings Changes

SLNO has been the topic of several research reports. Oppenheimer cut their target price on Soleno Therapeutics from $110.00 to $80.00 and set an “outperform” rating on the stock in a research note on Wednesday, March 18th. HC Wainwright lowered their price objective on shares of Soleno Therapeutics from $120.00 to $100.00 and set a “buy” rating on the stock in a report on Wednesday, March 4th. Zacks Research lowered shares of Soleno Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, February 3rd. Robert W. Baird set a $107.00 price target on shares of Soleno Therapeutics in a research note on Tuesday, January 13th. Finally, Wolfe Research set a $60.00 price objective on shares of Soleno Therapeutics in a research note on Monday, January 12th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $102.00.

Soleno Therapeutics Stock Performance

The company has a market cap of $1.55 billion, a P/E ratio of 130.66 and a beta of -3.16. The company has a quick ratio of 5.55, a current ratio of 5.80 and a debt-to-equity ratio of 0.11. The stock has a 50 day moving average price of $38.52 and a two-hundred day moving average price of $48.51.

Soleno Therapeutics (NASDAQ:SLNO) last announced its earnings results on Wednesday, February 25th. The company reported $0.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.64 by $0.16. The business had revenue of $91.73 million for the quarter, compared to analyst estimates of $88.55 million. On average, research analysts predict that Soleno Therapeutics, Inc. will post -3.72 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Soleno Therapeutics

Large investors have recently bought and sold shares of the company. Wellington Management Group LLP increased its holdings in Soleno Therapeutics by 272.3% in the 3rd quarter. Wellington Management Group LLP now owns 2,312,095 shares of the company’s stock valued at $156,298,000 after buying an additional 1,691,057 shares during the period. Braidwell LP bought a new stake in shares of Soleno Therapeutics during the 3rd quarter worth approximately $86,662,000. Janus Henderson Group PLC increased its stake in Soleno Therapeutics by 18.5% in the fourth quarter. Janus Henderson Group PLC now owns 7,178,354 shares of the company’s stock valued at $332,302,000 after acquiring an additional 1,122,015 shares during the last quarter. Invesco Ltd. raised its position in Soleno Therapeutics by 132.3% during the third quarter. Invesco Ltd. now owns 1,500,525 shares of the company’s stock valued at $101,435,000 after purchasing an additional 854,551 shares in the last quarter. Finally, Commodore Capital LP lifted its stake in Soleno Therapeutics by 121.3% during the third quarter. Commodore Capital LP now owns 1,350,000 shares of the company’s stock worth $91,260,000 after purchasing an additional 740,000 shares during the last quarter. 97.42% of the stock is currently owned by institutional investors and hedge funds.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.